

# Grzegorz S Nowakowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5724707/publications.pdf>

Version: 2024-02-01

249  
papers

5,031  
citations

117453

34  
h-index

110170

64  
g-index

250  
all docs

250  
docs citations

250  
times ranked

6719  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
2	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	0.7	15
3	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. <i>Blood Cancer Journal</i> , 2022, 12, 1.	2.8	7
4	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts. <i>HemaSphere</i> , 2022, 6, e680.	1.2	0
5	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	3.2	16
6	67-Year-Old Woman With Diarrhea and Weight Loss. <i>Mayo Clinic Proceedings</i> , 2022, 97, 364-369.	1.4	0
7	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
8	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. <i>Current Treatment Options in Oncology</i> , 2022, 23, 155-170.	1.3	17
9	Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	0.8	0
10	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
11	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
12	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
13	<sc>RNAseq</sc> identification of <sc>FISH</sc> â€œcryptic <i><sc>BCL6</sc> :: <sc>TP63</sc></i> rearrangement in <sc>ALK</sc> â€œnegative anaplastic large cell lymphoma. <i>Histopathology</i> , 2022, , .	1.6	4
14	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.	0.8	68
15	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	0.8	0
16	Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6530-6530.	0.8	2
17	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7559-7559.	0.8	1
18	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3084-3084.	0.8	0

#	ARTICLE	IF	CITATIONS
19	frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2022, 40, TPS7590-TPS7590.	0.8	1
20	Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2022, 40, e19553-e19553.	0.8	0
21	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. Journal of Clinical Oncology, 2022, 40, 7575-7575.	0.8	3
22	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	3.2	15
23	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	3.3	28
24	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.	0.8	65
25	Testicular <sup>FDG</sup>PET</sup>/<sup>CT</sup> uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	2.0	3
26	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	2.8	9
27	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. International Journal of Cancer, 2021, 149, 535-545.	2.3	4
28	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Advances, 2021, 5, 1379-1387.	2.5	18
29	Relapsed/Refractory International Prognostic Index (R<sup>IPI</sup>): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
30	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 2021, 39, 1329-1338.	0.8	60
31	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 1317-1328.	0.8	132
32	Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal, 2021, 11, 68.	2.8	41
33	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. Journal of Clinical Oncology, 2021, 39, TPS7571-TPS7571.	0.8	2
34	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, e19501-e19501.	0.8	0
35	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. Journal of Clinical Oncology, 2021, 39, e19547-e19547.	0.8	2
36	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. Journal of Clinical Oncology, 2021, 39, 7542-7542.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2021, 39, e13569-e13569.	0.8	1
38	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. Journal of Clinical Oncology, 2021, 39, 7530-7530.	0.8	1
39	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 7522-7522.	0.8	3
40	Impact of Organ Functionâ€‘Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	0.8	16
41	Outcomes in mantle cell lymphoma with central nervous system involvement.. Journal of Clinical Oncology, 2021, 39, e19527-e19527.	0.8	4
42	First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.. Journal of Clinical Oncology, 2021, 39, 7540-7540.	0.8	8
43	Diffuse large B-cell lymphoma with leukemic involvement.. Journal of Clinical Oncology, 2021, 39, e19552-e19552.	0.8	0
44	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	2.0	5
45	Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).. Journal of Clinical Oncology, 2021, 39, 7538-7538.	0.8	4
46	Assessment of fixedâ€‘duration therapies for treatmentâ€‘naïve <sc>WaldenstrÃ¶m</sc> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
47	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	2.8	4
48	Lack of intrafollicular memory CD4â€‘+â€‘T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	2.8	27
49	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 2625-2636.	0.6	3
50	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6124-6134.	3.2	24
51	Outcomes in primary cutaneous diffuse large Bâ€‘cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	0.8	8
52	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
53	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	2.8	3
54	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. Blood, 2021, 138, 1415-1415.	0.6	1

#	ARTICLE	IF	CITATIONS
55	A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR) Tj ETQq1 1 0.784314 rgB1/Overlook	0.6	1
56	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	0.6	8
57	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	1.1	1
58	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	0.6	1
59	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). Blood, 2021, 138, 3564-3564.	0.6	1
60	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. Blood, 2021, 138, 3523-3523.	0.6	0
61	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	0.6	2
62	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood, 2021, 138, 2429-2429.	0.6	1
63	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	0.6	0
64	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. Blood, 2021, 138, 2412-2412.	0.6	2
65	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. Blood, 2021, 138, 2524-2524.	0.6	1
66	Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. Blood, 2021, 138, 3549-3549.	0.6	0
67	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	0.6	0
68	A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 52-52.	0.6	3
69	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 3556-3556.	0.6	2
70	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. Blood, 2021, 138, 2527-2527.	0.6	3
71	Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma. Clinical Advances in Hematology and Oncology, 2021, 19, 284-287.	0.3	1
72	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. Haematologica, 2020, 105, e72-e75.	1.7	11

#	ARTICLE	IF	CITATIONS
73	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	1.7	105
74	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
75	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
76	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. <i>Leukemia</i> , 2020, 34, 1467-1471.	3.3	7
77	Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
78	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
79	Holistic review for hematology&oncology fellowship applicants: A new paradigm?. <i>American Journal of Hematology</i> , 2020, 95, 1124-1126.	2.0	1
80	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
81	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14
82	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	2.8	72
83	Treatment of Aggressive B Cell Lymphomas: Updates in 2019. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 225-234.	1.2	7
84	A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas. <i>Journal of Hematopathology</i> , 2020, 13, 127-135.	0.2	2
85	ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. <i>Future Oncology</i> , 2020, 16, 991-999.	1.1	12
86	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 203-210.	1.2	10
87	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. <i>Blood</i> , 2020, 136, 27-28.	0.6	2
88	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
89	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
90	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8020-8020.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 395-400.	0.2	1
92	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
93	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
94	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
95	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
96	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
97	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
98	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <i>Leukemia and Lymphoma</i> , 2019, 60, 559-561.	0.6	9
99	T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. <i>British Journal of Haematology</i> , 2019, 185, 140-142.	1.2	9
100	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
101	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. <i>PET Clinics</i> , 2019, 14, 307-315.	1.5	8
102	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
103	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
104	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
105	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
106	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
107	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
108	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277

#	ARTICLE	IF	CITATIONS
109	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. Clinical Epidemiology, 2019, Volume 11, 987-996.	1.5	5
110	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	3.3	28
111	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. American Journal of Hematology, 2019, 94, 291-298.	2.0	40
112	Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice. Journal of Cancer Education, 2019, 34, 1219-1224.	0.6	10
113	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2019, 134, 347-347.	0.6	2
114	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. Blood, 2019, 134, 4092-4092.	0.6	4
115	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	0.6	2
116	Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. Blood, 2019, 134, 5330-5330.	0.6	1
117	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2019, 134, 467-467.	0.6	29
118	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	0.6	7
119	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. Blood, 2019, 134, 2877-2877.	0.6	3
120	Coplanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. Blood, 2019, 134, 4090-4090.	0.6	1
121	Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood, 2019, 134, 5345-5345.	0.6	24
122	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. Blood, 2019, 134, 2859-2859.	0.6	9
123	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. Blood, 2019, 134, 4129-4129.	0.6	1
124	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. Blood, 2019, 134, 5327-5327.	0.6	4
125	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	0.6	0
126	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study. Blood, 2019, 134, 3475-3475.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5352-5352.	0.6	0
128	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	0.6	0
129	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
130	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
131	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
132	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	0.6	3
133	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
134	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
135	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
136	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
137	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
138	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
139	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
140	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
141	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
142	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
143	The diagnosis and treatment of primary vitreoretinal lymphoma: a review. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 18.	0.9	85
144	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 57.	6.9	19

#	ARTICLE	IF	CITATIONS
145	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
146	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.2	6
147	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445.	0.6	9
148	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
149	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
150	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
151	Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4168-4168.	0.6	8
152	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
153	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4139-4139.	0.6	0
154	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018, 132, 5401-5401.	0.6	1
155	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 4208-4208.	0.6	0
156	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
157	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0
158	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. <i>Blood</i> , 2018, 132, 2236-2236.	0.6	0
159	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	0.6	0
160	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
161	Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2017, 13, 859-862.	1.1	4
162	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
164	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
165	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	2.0	8
166	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
167	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
168	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 26245-26255.	0.8	14
169	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
170	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
171	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
172	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
173	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
174	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	0.6	2
175	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. <i>Blood</i> , 2016, 128, 3033-3033.	0.6	2
176	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
177	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
178	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
179	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.	0.6	0
180	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1749-1749.	0.6	0
182	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	0.6	83
183	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	0.6	18
184	Evolution: IMiDs to PPMs, revolution in DLBCL?. <i>Blood</i> , 2015, 126, 698-700.	0.6	5
185	ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e449-e457.	1.8	102
186	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
187	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.2	11
188	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1658-1671.	1.9	122
189	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
190	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
191	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
192	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1
193	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015, 126, 813-813.	0.6	1
194	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8600-TPS8600.	0.8	1
195	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	0.6	0
196	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	0.6	0
197	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	0.6	0
198	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	0.6	0

#	ARTICLE	IF	CITATIONS
199	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	0.6	0
200	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	0.6	0
201	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	3.2	86
202	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
203	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
204	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4306-4306.	0.6	0
205	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	0.6	8
206	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012, 120, 1525-1525.	0.6	0
207	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012, 120, 1527-1527.	0.6	0
208	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2700-2700.	0.6	31
209	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
210	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. <i>Blood</i> , 2012, 120, 2741-2741.	0.6	0
211	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
212	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
213	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012, 120, 2634-2634.	0.6	0
214	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment " a Single Institution Experience. <i>Blood</i> , 2011, 118, 1580-1580.	0.6	1
215	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011, 118, 1640-1640.	0.6	1
216	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011, 118, 2836-2836.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	0.6	0
218	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	0.6	0
219	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	0.6	0
220	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. Blood, 2011, 118, 3642-3642.	0.6	0
221	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	0.6	1
222	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	0.6	0
223	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylooxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	0.6	2
224	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 412-417.	0.8	75
225	Phase I Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. Blood, 2010, 116, 2802-2802.	0.6	2
226	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	0.6	5
227	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€œ Single Institution Experience. Blood, 2010, 116, 4168-4168.	0.6	5
228	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	0.6	2
229	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. Blood, 2010, 116, 3088-3088.	0.6	0
230	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	0.6	0
231	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	0.6	0
232	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2862-2862.	0.6	0
233	Reply to R.S. Go. Journal of Clinical Oncology, 2009, 27, e45-e45.	0.8	1
234	Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 1844-1849.	0.8	71

#	ARTICLE	IF	CITATIONS
235	Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.. Blood, 2009, 114, 92-92.	0.6	2
236	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. Blood, 2008, 112, 3124-3124.	0.6	2
237	Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. Mayo Clinic Proceedings, 2007, 82, 449-453.	1.4	55
238	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. Blood, 2007, 110, 337-337.	0.6	1
239	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	0.6	0
240	A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer. Clinical Cancer Research, 2006, 12, 6087-6093.	3.2	112
241	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. Blood, 2006, 108, 2785-2785.	0.6	1
242	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. Blood, 2006, 108, 300-300.	0.6	5
243	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. Blood, 2006, 108, 586-586.	0.6	0
244	Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. British Journal of Haematology, 2005, 128, 490-492.	1.2	20
245	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. Blood, 2005, 106, 707-707.	0.6	14
246	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. Blood, 2005, 106, 4698-4698.	0.6	0
247	Targeting V $\alpha$ -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V $\alpha$ -4 Therapy.. Blood, 2005, 106, 1182-1182.	0.6	0
248	Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 1919-1919.	0.6	1
249	Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGL).. Blood, 2004, 104, 2819-2819.	0.6	0